vs
Side-by-side financial comparison of SANFILIPPO JOHN B & SON INC (JBSS) and Orthofix Medical Inc. (OFIX). Click either name above to swap in a different company.
SANFILIPPO JOHN B & SON INC is the larger business by last-quarter revenue ($314.8M vs $219.9M, roughly 1.4× Orthofix Medical Inc.). SANFILIPPO JOHN B & SON INC runs the higher net margin — 5.7% vs -1.0%, a 6.7% gap on every dollar of revenue. On growth, SANFILIPPO JOHN B & SON INC posted the faster year-over-year revenue change (4.6% vs 2.0%). SANFILIPPO JOHN B & SON INC produced more free cash flow last quarter ($40.0M vs $16.8M). Over the past eight quarters, Orthofix Medical Inc.'s revenue compounded faster (8.0% CAGR vs 7.6%).
John B. Sanfilippo & Son Inc. (JBSS) is a leading US processor, marketer and distributor of high-quality tree nuts, peanuts, dried fruits, and value-added snack products. It serves retail, foodservice, and industrial ingredient customers primarily across North America, offering both branded and private label product lines.
Orthofix Medical Inc. is a global medical device firm specializing in orthopedic care. It develops, manufactures and sells spinal implants, trauma care products, bone growth stimulation therapies and regenerative medicine offerings, serving orthopedic surgeons and healthcare providers across North America, Europe and Asia Pacific.
JBSS vs OFIX — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $314.8M | $219.9M |
| Net Profit | $18.0M | $-2.2M |
| Gross Margin | 18.8% | 71.1% |
| Operating Margin | 8.3% | 0.2% |
| Net Margin | 5.7% | -1.0% |
| Revenue YoY | 4.6% | 2.0% |
| Net Profit YoY | 32.1% | 92.4% |
| EPS (diluted) | $1.53 | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $314.8M | $219.9M | ||
| Q3 25 | $298.7M | $205.6M | ||
| Q2 25 | $269.1M | $203.1M | ||
| Q1 25 | $260.9M | $193.6M | ||
| Q4 24 | $301.1M | $215.7M | ||
| Q3 24 | $276.2M | $196.6M | ||
| Q2 24 | $269.6M | $198.6M | ||
| Q1 24 | $271.9M | $188.6M |
| Q4 25 | $18.0M | $-2.2M | ||
| Q3 25 | $18.7M | $-22.8M | ||
| Q2 25 | $13.5M | $-14.1M | ||
| Q1 25 | $20.2M | $-53.1M | ||
| Q4 24 | $13.6M | $-29.1M | ||
| Q3 24 | $11.7M | $-27.4M | ||
| Q2 24 | $10.0M | $-33.4M | ||
| Q1 24 | $13.5M | $-36.0M |
| Q4 25 | 18.8% | 71.1% | ||
| Q3 25 | 18.1% | 72.2% | ||
| Q2 25 | 18.1% | 68.7% | ||
| Q1 25 | 21.4% | 62.8% | ||
| Q4 24 | 17.4% | 69.0% | ||
| Q3 24 | 16.9% | 68.7% | ||
| Q2 24 | 18.5% | 67.8% | ||
| Q1 24 | 18.1% | 67.5% |
| Q4 25 | 8.3% | 0.2% | ||
| Q3 25 | 9.0% | -8.3% | ||
| Q2 25 | 7.5% | -7.9% | ||
| Q1 25 | 10.8% | -25.2% | ||
| Q4 24 | 6.4% | -5.3% | ||
| Q3 24 | 6.2% | -9.6% | ||
| Q2 24 | 5.4% | -12.5% | ||
| Q1 24 | 6.7% | -15.6% |
| Q4 25 | 5.7% | -1.0% | ||
| Q3 25 | 6.3% | -11.1% | ||
| Q2 25 | 5.0% | -6.9% | ||
| Q1 25 | 7.7% | -27.4% | ||
| Q4 24 | 4.5% | -13.5% | ||
| Q3 24 | 4.2% | -13.9% | ||
| Q2 24 | 3.7% | -16.8% | ||
| Q1 24 | 5.0% | -19.1% |
| Q4 25 | $1.53 | $-0.05 | ||
| Q3 25 | $1.59 | $-0.57 | ||
| Q2 25 | $1.15 | $-0.36 | ||
| Q1 25 | $1.72 | $-1.35 | ||
| Q4 24 | $1.16 | $-0.76 | ||
| Q3 24 | $1.00 | $-0.71 | ||
| Q2 24 | $0.85 | $-0.88 | ||
| Q1 24 | $1.15 | $-0.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4M | $82.0M |
| Total DebtLower is stronger | $28.8M | — |
| Stockholders' EquityBook value | $370.1M | $450.0M |
| Total Assets | $617.7M | $850.6M |
| Debt / EquityLower = less leverage | 0.08× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4M | $82.0M | ||
| Q3 25 | $714.0K | $62.9M | ||
| Q2 25 | $585.0K | $65.6M | ||
| Q1 25 | $1.3M | $58.0M | ||
| Q4 24 | $336.0K | $83.2M | ||
| Q3 24 | $442.0K | $30.1M | ||
| Q2 24 | $484.0K | $26.4M | ||
| Q1 24 | $377.0K | $27.0M |
| Q4 25 | $28.8M | — | ||
| Q3 25 | $29.8M | $157.2M | ||
| Q2 25 | $14.6M | $157.0M | ||
| Q1 25 | $5.8M | $156.9M | ||
| Q4 24 | $6.0M | $157.0M | ||
| Q3 24 | $6.2M | $118.5M | ||
| Q2 24 | $6.4M | $118.0M | ||
| Q1 24 | $6.6M | $118.2M |
| Q4 25 | $370.1M | $450.0M | ||
| Q3 25 | $362.8M | $442.5M | ||
| Q2 25 | $360.7M | $458.3M | ||
| Q1 25 | $346.6M | $458.3M | ||
| Q4 24 | $325.6M | $503.1M | ||
| Q3 24 | $310.8M | $525.9M | ||
| Q2 24 | $322.6M | $546.0M | ||
| Q1 24 | $321.8M | $570.3M |
| Q4 25 | $617.7M | $850.6M | ||
| Q3 25 | $598.7M | $832.6M | ||
| Q2 25 | $597.6M | $837.2M | ||
| Q1 25 | $590.0M | $823.1M | ||
| Q4 24 | $545.3M | $893.3M | ||
| Q3 24 | $519.4M | $867.9M | ||
| Q2 24 | $515.6M | $882.0M | ||
| Q1 24 | $491.9M | $906.0M |
| Q4 25 | 0.08× | — | ||
| Q3 25 | 0.08× | 0.36× | ||
| Q2 25 | 0.04× | 0.34× | ||
| Q1 25 | 0.02× | 0.34× | ||
| Q4 24 | 0.02× | 0.31× | ||
| Q3 24 | 0.02× | 0.23× | ||
| Q2 24 | 0.02× | 0.22× | ||
| Q1 24 | 0.02× | 0.21× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $62.5M | $27.7M |
| Free Cash FlowOCF − Capex | $40.0M | $16.8M |
| FCF MarginFCF / Revenue | 12.7% | 7.6% |
| Capex IntensityCapex / Revenue | 7.1% | 4.9% |
| Cash ConversionOCF / Net Profit | 3.48× | — |
| TTM Free Cash FlowTrailing 4 quarters | $32.8M | $-1.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $62.5M | $27.7M | ||
| Q3 25 | $32.1M | $12.4M | ||
| Q2 25 | $36.5M | $11.6M | ||
| Q1 25 | $-25.9M | $-18.4M | ||
| Q4 24 | $11.0M | $23.7M | ||
| Q3 24 | $8.9M | $11.7M | ||
| Q2 24 | $35.2M | $9.0M | ||
| Q1 24 | $5.3M | $-18.6M |
| Q4 25 | $40.0M | $16.8M | ||
| Q3 25 | $7.3M | $2.5M | ||
| Q2 25 | $23.0M | $4.5M | ||
| Q1 25 | $-37.6M | $-25.1M | ||
| Q4 24 | $-2.7M | $15.2M | ||
| Q3 24 | $-3.0M | $6.3M | ||
| Q2 24 | $24.4M | $-360.0K | ||
| Q1 24 | $-1.3M | $-29.1M |
| Q4 25 | 12.7% | 7.6% | ||
| Q3 25 | 2.4% | 1.2% | ||
| Q2 25 | 8.6% | 2.2% | ||
| Q1 25 | -14.4% | -13.0% | ||
| Q4 24 | -0.9% | 7.0% | ||
| Q3 24 | -1.1% | 3.2% | ||
| Q2 24 | 9.0% | -0.2% | ||
| Q1 24 | -0.5% | -15.4% |
| Q4 25 | 7.1% | 4.9% | ||
| Q3 25 | 8.3% | 4.8% | ||
| Q2 25 | 5.0% | 3.5% | ||
| Q1 25 | 4.5% | 3.5% | ||
| Q4 24 | 4.5% | 4.0% | ||
| Q3 24 | 4.3% | 2.7% | ||
| Q2 24 | 4.0% | 4.7% | ||
| Q1 24 | 2.4% | 5.6% |
| Q4 25 | 3.48× | — | ||
| Q3 25 | 1.72× | — | ||
| Q2 25 | 2.70× | — | ||
| Q1 25 | -1.29× | — | ||
| Q4 24 | 0.81× | — | ||
| Q3 24 | 0.77× | — | ||
| Q2 24 | 3.52× | — | ||
| Q1 24 | 0.39× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JBSS
| Sales Channel Directly To Consumer | $263.2M | 84% |
| Sales Channel Commercial Ingredients | $28.0M | 9% |
| Sales Channel Contract Packaging | $23.6M | 8% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
